Top

Published in:

01-08-2020 | Coronavirus | Correspondence

Targeting the immunology of coronavirus disease-19: synchronization creates symphony

Authors: Sakir Ahmed, Prajna Anirvan

Published in: Rheumatology International | Issue 8/2020

Excerpt

Currently, there is a deluge of data on coronavirus disease 2019 (COVID-19). There are proponents of different therapies to target COVID-19 including antivirals, anti-inflammatory, and immune therapies [1‐3]. There is an emerging role of thrombosis in disease pathogenesis [4]. The current emphasis seems to have shifted to predominantly immunology-based strategies like advocating mass vaccination drives for BCG, pneumococcus, and influenza; neutralizing the virus with convalescent plasma or monoclonal antibodies and testing interferon-based therapies [2]. Rheumatologists have a special say in the situation since anti-inflammatory, immune, and even anti-thrombotic therapies are their forte [5]. We feel the need of the hour is to have a strategized and synchronized attack on COVID-19 on various fronts. Thus, it is pertinent for rheumatologists and immunologists to know about, and integrate, various diverse strategies in the battle against COVID-19. …

Stebbing J, Phelan A, Griffin I et al (2020) COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 20:400–402. https://doi.org/10.1016/S1473-3099(20)30132-8 CrossRefPubMedPubMedCentral

Gasparyan AY, Misra DP, Yessirkepov M, Zimba O (2020) Perspectives of Immune Therapy in Coronavirus Disease 2019. J Korean Med Sci 35:e176. https://doi.org/10.3346/jkms.2020.35.e176 CrossRefPubMedPubMedCentral

Misra DP, Agarwal V, Gasparyan AY, Zimba O (2020) Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. https://doi.org/10.1007/s10067-020-05073-9 CrossRefPubMedPubMedCentral

Klok FA, Kruip MJHA, van der Meer NJM et al (2020) Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. https://doi.org/10.1016/j.thromres.2020.04.041 CrossRefPubMedPubMedCentral

Kernan KF, Canna SW (2020) Should COVID-19 take advice from rheumatologists? Lancet Rheumatol. https://doi.org/10.1016/S2665-9913(20)30129-6 CrossRefPubMedPubMedCentral

Lewnard JA, Lo NC (2020) Scientific and ethical basis for social-distancing interventions against COVID-19. Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(20)30190-0 CrossRefPubMedPubMedCentral

Choe YJ, Choi EH (2020) Are we ready for coronavirus disease 2019 arriving at schools? J Korean Med Sci. https://doi.org/10.3346/jkms.2020.35.e127 CrossRefPubMedPubMedCentral

Lee J (2020) COVID-19 Screening Center: how to Balance between the Speed and Safety? J Korean Med Sci. https://doi.org/10.3346/jkms.2020.35.e157 CrossRefPubMedPubMedCentral

Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. https://doi.org/10.1016/j.cell.2020.02.052 CrossRefPubMedPubMedCentral

10.

Sarma P, Kaur H, Kumar H et al (2020) Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: a systematic review and meta-analysis. J Med Virol. https://doi.org/10.1002/jmv.25898 CrossRefPubMedPubMedCentral

11.

Ahmed S, Anirvan P (2020) Reply to rheumatologists’ perspective on coronavirus disease 19: is heparin the dark horse for COVID-19? Clin Rheumatol. https://doi.org/10.1007/s10067-020-05145-w CrossRefPubMedPubMedCentral

12.

Vaduganathan M, Vardeny O, Michel T et al (2020) Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med 382:1653–1659. https://doi.org/10.1056/NEJMsr2005760 CrossRefPubMed

13.

Tang N, Bai H, Chen X et al (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost JTH. https://doi.org/10.1111/jth.14817 CrossRefPubMed

14.

O’Brien TR, Thomas DL, Jackson SS et al (2020) Weak induction of interferon expression by SARS-CoV-2 supports clinical trials of interferon lambda to treat early COVID-19. Clin Infect Dis Off Publ Infect Dis Soc Am. https://doi.org/10.1093/cid/ciaa453 CrossRef

15.

Sallard E, Lescure F-X, Yazdanpanah Y et al (2020) Type 1 interferons as a potential treatment against COVID-19. Antivir Res 178:104791. https://doi.org/10.1016/j.antiviral.2020.104791 CrossRefPubMed

16.

Shalhoub S (2020) Interferon beta-1b for COVID-19. The Lancet. https://doi.org/10.1016/S0140-6736(20)31101-6 CrossRef

17.

Richardson P, Griffin I, Tucker C et al (2020) Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet Lond Engl 395:e30–e31. https://doi.org/10.1016/S0140-6736(20)30304-4 CrossRef

18.

Maldini C, Ellis G, Riley JL (2018) CAR T cells for infection, autoimmunity and allotransplantation. Nat Rev Immunol 18:605–616. https://doi.org/10.1038/s41577-018-0042-2 CrossRefPubMedPubMedCentral

19.

Campbell CM, Kahwash R (2020) Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis? Circulation. https://doi.org/10.1161/CIRCULATIONAHA.120.047419 CrossRefPubMedPubMedCentral

20.

Wang R, Xiao H, Guo R et al (2015) The role of C5a in acute lung injury induced by highly pathogenic viral infections. Emerg Microbes Infect 4:1–7. https://doi.org/10.1038/emi.2015.28 CrossRef

21.

Hung IF-N, Lung K-C, Tso EY-K et al (2020) Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. The Lancet. https://doi.org/10.1016/S0140-6736(20)31042-4 CrossRefPubMed

22.

Solidarity clinical trial for COVID-19 treatments (2020) https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments. Accessed 11 May 2020

Title: Targeting the immunology of coronavirus disease-19: synchronization creates symphony
Authors: Sakir Ahmed
Prajna Anirvan
Publication date: 01-08-2020
Publisher: Springer Berlin Heidelberg
Keywords: Coronavirus
Influenza
Acute Respiratory Distress-Syndrome
COVID-19
Interferon
Published in: Rheumatology International / Issue 8/2020
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-020-04624-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Targeting the immunology of coronavirus disease-19: synchronization creates symphony

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2020

Crystalglobulinemia manifested as acute renal failure and thrombotic vasculopathy

Demographic and clinical characteristics of patients with ANCA-positive vasculitis in a Colombian University Hospital over a 12-year period: 2005–2017

Provisional seven-item criteria for the diagnosis of polyarteritis nodosa

The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk

Implications of COVID-19 in pediatric rheumatology

Peripheral neuropathy and health-related quality of life in patients with primary Sjögren’s syndrome: a preliminary report

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page